31 Uveal Melanoma

Uveal Melanoma

20

THE GEC ESTROHANDBOOKOF BRACHYTHERAPY | Part II Clinical Practice Version 1 - 15/04/2020

60. Rospond-Kubiak I, Wróblewska-Zierhoffer M, Twardosz-Pawlik H, Kocięcki J. Ruthenium brachytherapy for uveal melanoma - single institution experience. J Contemp Brachytherapy. 2017;9(6):548–552. doi:10.5114/jcb.2017.72606 61. Rouberol F, Roy P, Kodjikian L, Gérard JP, Jean-Louis B, Grange JD. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta- rays). Am J Ophthalmol. 2004;137(5):893–900. doi:10.1016/j.ajo.2003.12.032 62. Seibel I, Cordini D, Rehak M, et al. Local Recurrence After Primary Proton BeamTherapy in Uveal Melanoma: Risk Factors, Retreatment Approaches, and Outcome. Am J Ophthalmol. 2015;160(4):628–636. doi:10.1016/j.ajo.2015.06.017 63. Shah SU, Shields CL, Bianciotto CG, et al. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma. Ophthalmology. 2014;121(1):269–275. doi:10.1016/j. ophtha.2013.08.039 64. Shields CL, Cater J, Shields JA, et al. Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol. 2002;120(7):933–940. doi:10.1001/archopht.120.7.933 65. Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127(8):989–998. doi:10.1001/archophthalmol.2009.208 66. Shields CL, Kaliki S, Furuta M, Fulco E, Alarcon C, Shields JA. American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category)predictsprognosis in7731patients.Ophthalmology.2013;120(10):2066– 2071. doi:10.1016/j.ophtha.2013.03.012 67. Shields CL, Kels JG, Shields JA. Melanoma of the eye: revealing hidden secrets, one at a time. Clin Dermatol. 2015;33(2):183–196. doi:10.1016/j. clindermatol.2014.10.010 68. Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118(9):1219–1228. doi:10.1001/archopht.118.9.1219 69. Shields CL, Shields JA, Karlsson U, Markoe AM, Brady LW. Reasons for enucleation after plaque radiotherapy for posterior uveal melanoma. Clinical findings.Ophthalmology.1989;96(6):919–924.doi:10.1016/s0161-6420(89)32806- 5 70. Shields JA, Shields C. Intraocular Tumours. A Text and Atlas. Saunders, Philadelphia, 1992. 71. Siedlecki J, Reiterer V, Leicht S, et al. Incidence of secondary glaucoma after treatmentofuvealmelanomawithroboticradiosurgeryversusbrachytherapy.Acta Ophthalmol. 2017;95(8):e734–e739. doi:10.1111/aos.13418 72. Sim L. Novel application of 3D printing in brachytherapy using MED610 3D printed insert for I-125 ROPES eye plaque. Australas Phys Eng Sci Med. 2016;39(4):863–870. doi:10.1007/s13246-016-0480-8 73. Stöckel E, Eichmann M, Flühs D, et al. Dose Distributions and Treatment Margins in Ocular Brachytherapy with 106Ru Eye Plaques. Ocul Oncol Pathol. 2018;4(2):122–128. doi:10.1159/000479558 74. Summanen P, Immonen I, Kivelä T, Tommila P, Heikkonen J, Tarkkanen A. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma. Br J Ophthalmol. 1996;80(8):732–739. doi:10.1136/bjo.80.8.732 75. Tabandeh H, Chaudhry NA, Murray TG, et al. Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. Am J Ophthalmol. 2000;129(2):199–204. doi:10.1016/s0002- 9394(99)00315-3 76. Tagliaferri L, Pagliara MM, Boldrini L, et al. INTERACTS (INTErventional Radiotherapy ACtive Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures. J Contemp Brachytherapy. 2017;9(3):287–295. doi:10.5114/jcb.2017.68761 77. Tagliaferri L, Pagliara MM, Fionda B, et al. Personalized re-treatment strategy for uveal melanoma local recurrences after interventional radiotherapy (brachytherapy): single institution experience and systematic literature review. J Contemp Brachytherapy. 2019;11(1):54–60. doi:10.5114/jcb.2019.82888 78. TagliaferriL,PagliaraMM,MasciocchiC,etal.Nomogramforpredictingradiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma. J Contemp Brachytherapy. 2017;9(6):540–547. doi:10.5114/ jcb.2017.71795

79. Takiar V, Voong KR, Gombos DS, et al. A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma. Pract Radiat Oncol. 2015;5(3):e169–e176. doi:10.1016/j.prro.2014.09.005 80. Amin MB, Edge SB, Greene F, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp 805–17 81. Virgili G, Gatta G, Ciccolallo L, et al. Incidence of uveal melanoma in Europe. Ophthalmology.2007;114(12):2309–2315 doi:10.1016/j. ophtha.2007.01.032 82. Zoberi JE, Garcia-Ramirez J, Hedrick S, et al. MRI-based treatment planning and dose delivery verification for intraocularmelanoma brachytherapy. Brachytherapy. 2018;17(1):31–39. doi:10.1016/j.brachy.2017.07.011